{"ticker": {"uuid": "17501b0b-b197-4682-9ebc-e2ed7b51eac7", "symbol": "BOLT", "name": "Bolt Biotherapeutics", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "BOLT Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "Bolt Biotherapeutics, Inc. (BOLT) has a current stock price of $4.28, having increased by 1.79% in the past 24 hours. Analysts provide a wide forecast range for BOLT, with a maximum estimate of $75.00 and a minimum of $7.00. The company's stock has experienced a significant decre", "url": "https://www.tradingview.com/symbols/NASDAQ-BOLT/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T20:10:57", "published_display": "26 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bolt Biotherapeutics Inc (BOLT) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Bolt Biotherapeutics Inc (BOLT) has a weak financial status with a current financial score of 5.62, ranking low within the Biotechnology & Medical Research industry. The company's operating efficiency is low, demonstrated by a significant year-over-year revenue decrease of 97.87%", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bolt/financial-health", "source_name": "TradingKey", "published_at": "2026-06-26T20:10:57", "published_display": "26 Jun 2026 20:10", "sentiment": "negative", "sentiment_pct": 19, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A419U9 Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Bolt Biotherapeutics, Inc. (A419U9) stock, including analyst price targets and ratings. It also details the company's financial performance, such as recent earnings and revenue, upcoming earnings dates, and employee count. The article notes th", "url": "https://www.tradingview.com/symbols/LSX-A419U9/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T14:40:12", "published_display": "26 Jun 2026 14:40", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bolt Biotherapeutics, Inc. Actuals & Estimates (MUN:6LP0)", "summary": "This article provides financial actuals and estimates for Bolt Biotherapeutics, Inc. (MUN:6LP0), including analyst forecasts for its stock price, upcoming earnings reports, and past financial performance. It highlights key metrics like earnings per share, revenue, net income, EBI", "url": "https://www.tradingview.com/symbols/MUN-6LP0/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T21:41:15", "published_display": "25 Jun 2026 21:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Bolt Biotherapeutics, Inc. \u2013 NASDAQ:BOLT", "summary": "This article provides financial information for Bolt Biotherapeutics, Inc. (NASDAQ: BOLT), specifically focusing on its enterprise value to revenue forward. The content appears to be a stub or a placeholder page from TradingView, indicating where more detailed financial metrics f", "url": "https://www.tradingview.com/symbols/NASDAQ-BOLT/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T19:40:12", "published_display": "25 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Bolt Biotherapeutics, Inc. \u2013 NASDAQ:BOLT", "summary": "The article discusses the \"Price to book forward\" metric for Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) as presented on TradingView. It specifies that this financial data point is for the BOLT Nasdaq Stock Market, with the market currently closed and no trades. The article is prim", "url": "https://www.tradingview.com/symbols/NASDAQ-BOLT/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T19:12:17", "published_display": "25 Jun 2026 19:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "6LP0 Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Bolt Biotherapeutics, Inc. (6LP0) stock. It includes analyst opinions on future prices, past earnings, revenue, net income, and confirms that the company does not pay dividends. The report also details the company's employee c", "url": "https://www.tradingview.com/symbols/MUN-6LP0/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T02:42:51", "published_display": "25 Jun 2026 02:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bolt Biotherapeutics Inc (BOLT) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Bolt Biotherapeutics Inc (BOLT), detailing analyst ratings, price targets, and revenue expectations. The company currently holds an earnings forecast score of 7.00 within the Biotechnology & Medical Research industry, with an average", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bolt/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T17:39:26", "published_display": "18 Jun 2026 17:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bolt Biotherapeutics Inc (BOLT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey examines Bolt Biotherapeutics Inc. (BOLT)'s revenue breakdown. It states that relevant data regarding business segments, regional revenue, and profit contribution has not yet been disclosed by the company. The stock closed at $4.030, down 4.28%.", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bolt/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T17:17:42", "published_display": "18 Jun 2026 17:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bolt Biotherapeutics Inc (BOLT) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article provides an overview of Bolt Biotherapeutics Inc (BOLT)'s shareholder structure, detailing its major shareholders and institutional holdings. It lists key shareholders like Sofinnova Investments, Inc. and Vivo Capital, LLC, categorizes shareholders by type, and prese", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bolt/ownership", "source_name": "TradingKey", "published_at": "2026-06-18T17:17:42", "published_display": "18 Jun 2026 17:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bolt Biotherapeutics Inc (BOLT) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Bolt Biotherapeutics Inc (BOLT), detailing its current price momentum score, support and resistance levels, and technical indicator readings. It shows that BOLT has a price momentum score of 6.62 and is trading between a resistance of", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bolt/technical", "source_name": "TradingKey", "published_at": "2026-06-18T16:39:39", "published_display": "18 Jun 2026 16:39", "sentiment": "negative", "sentiment_pct": 12, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bolt Biotherapeutics Inc (BOLT) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Bolt Biotherapeutics Inc's (BOLT) dividend history and stock split events. It indicates that the company has not distributed any dividends in the past five years. However, it lists a significant stock split event described as a 20-for-1 merger", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bolt/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T16:17:42", "published_display": "18 Jun 2026 16:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bolt Biotherapeutics Inc (BOLT) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "This article provides a risk assessment for Bolt Biotherapeutics Inc (BOLT), categorizing it within the Biotechnology & Medical Research industry. It details the company's current risk assessment score, beta value, and various volatility and liquidity metrics. The analysis indica", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bolt/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-18T09:12:07", "published_display": "18 Jun 2026 09:12", "sentiment": "negative", "sentiment_pct": 40, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bolt Biotherapeutics Inc (BOLT) Institutional Confidence", "summary": "Bolt Biotherapeutics Inc (BOLT) has an institutional shareholding score of 3.00, placing it 193rd out of 388 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 26.88%, which is a quarter-over-quarter decrease of 51.40%. James Sim", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bolt/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T05:12:07", "published_display": "18 Jun 2026 05:12", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bolt Biotherapeutics Inc (BOLT) Valuation: PE, PB & Fair Value Analysis", "summary": "Bolt Biotherapeutics Inc (BOLT) has a current valuation score of 9.01, placing it 67th out of 388 companies in the Biotechnology & Medical Research industry. The company's P/E ratio stands at -0.26, reflecting a significant drop from its recent high but an increase from its recen", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bolt/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T00:12:07", "published_display": "18 Jun 2026 00:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bolt Biotherapeutics (BOLT) director receives 5,000 stock options at $4.43 strike", "summary": "Bolt Biotherapeutics director Nicole Onetto was granted 5,000 stock options with an exercise price of $4.43 per share. These options are a compensation-related grant, not an open-market purchase, and will vest on the earlier of June 9, 2027, or the day before the next annual stoc", "url": "https://www.stocktitan.net/sec-filings/BOLT/form-4-bolt-biotherapeutics-inc-insider-trading-activity-569d1bf5212a.html", "source_name": "Stock Titan", "published_at": "2026-06-12T01:40:33", "published_display": "12 Jun 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bolt Biotherapeutics (BOLT) director receives 5,000 stock options at $4.43 exercise price", "summary": "Bolt Biotherapeutics director Laura Berner was granted 5,000 stock options with an exercise price of $4.43 per share, expiring on June 9, 2036. The options will vest on the earlier of June 9, 2027, or the day before the next annual stockholders' meeting, subject to continuous ser", "url": "https://www.stocktitan.net/sec-filings/BOLT/form-4-bolt-biotherapeutics-inc-insider-trading-activity-cddb88819838.html", "source_name": "Stock Titan", "published_at": "2026-06-11T20:39:07", "published_display": "11 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bolt Biotherapeutics (NASDAQ: BOLT) director receives 5,000-share stock option grant", "summary": "Bolt Biotherapeutics director Jakob Dupont was granted a stock option for 5,000 shares of common stock with an exercise price of $4.43 per share, expiring on June 9, 2036. The options will vest on the earlier of June 9, 2027, or the day before the next annual stockholder meeting,", "url": "https://www.stocktitan.net/sec-filings/BOLT/form-4-bolt-biotherapeutics-inc-insider-trading-activity-5b6e204fdc90.html", "source_name": "Stock Titan", "published_at": "2026-06-11T20:39:07", "published_display": "11 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bolt Biotherapeutics (BOLT) director receives 5,000 stock options at $4.43 strike price", "summary": "Bolt Biotherapeutics director Brian O\u2019Callaghan was granted 5,000 stock options with an exercise price of $4.43 per share, expiring on June 9, 2036. The options will vest on the earlier of June 9, 2027, or the day before the next annual stockholder meeting, provided continuous se", "url": "https://www.stocktitan.net/sec-filings/BOLT/form-4-bolt-biotherapeutics-inc-insider-trading-activity-b684a1f75138.html", "source_name": "Stock Titan", "published_at": "2026-06-11T20:39:07", "published_display": "11 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bolt Biotherapeutics (NASDAQ: BOLT) grants director options for 5,000 shares", "summary": "Bolt Biotherapeutics (NASDAQ: BOLT) director Kathleen LaPorte was granted stock options for 5,000 shares with an exercise price of $4.43 per share, expiring on June 9, 2036. The options will vest on the earlier of June 9, 2027, or the day before the next annual stockholder meetin", "url": "https://www.stocktitan.net/sec-filings/BOLT/form-4-bolt-biotherapeutics-inc-insider-trading-activity-db5570814a17.html", "source_name": "Stock Titan", "published_at": "2026-06-11T20:39:07", "published_display": "11 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BOLT - Bolt Biotherapeutics Inc Stock Price and Quote", "summary": "This article provides detailed financial data and news for Bolt Biotherapeutics Inc. (BOLT), including its stock price, key financial metrics, insider transactions, and a chronological list of company news and analyst ratings. The company is a clinical-stage biopharmaceutical fir", "url": "https://finviz.com/stock?t=BOLT", "source_name": "Finviz", "published_at": "2026-06-02T10:10:19", "published_display": "02 Jun 2026 10:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bolt Biotherapeutics Price Target Announced at $22.00/Share by Rodman & Renshaw", "summary": "Rodman & Renshaw has initiated coverage on Bolt Biotherapeutics (NASDAQ:BOLT), assigning a \"Buy\" rating and setting a price target of $22.00 per share. This target suggests a potential upside of 1150% from the stock's previous closing price.", "url": "https://www.moomoo.com/news/post/70782663/bolt-biotherapeutics-price-target-announced-at-22-00-share-by", "source_name": "Moomoo", "published_at": "2026-05-29T19:39:54", "published_display": "29 May 2026 19:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rodman & Renshaw initiates Bolt Biotherapeutics stock with buy rating By Investing.com", "summary": "Rodman & Renshaw initiated coverage on Bolt Biotherapeutics (NASDAQ:BOLT) with a buy rating and a $22.00 price target. The firm cited the company's Claudin 18.2 immune-stimulating antibody conjugate platform and a near-term clinical readout for BDC-4182 expected in Q3 2026 as key", "url": "https://in.investing.com/news/stock-market-news/rodman--renshaw-initiates-bolt-biotherapeutics-stock-with-buy-rating-93CH-5430912", "source_name": "Investing.com India", "published_at": "2026-05-29T08:39:07", "published_display": "29 May 2026 08:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rodman & Renshaw initiates Bolt Biotherapeutics stock with buy rating", "summary": "Rodman & Renshaw has initiated coverage on Bolt Biotherapeutics (NASDAQ:BOLT) with a \"buy\" rating and a price target of $22.00, citing the company's Claudin 18.2 immune-stimulating antibody conjugate platform. The firm anticipates a near-term clinical readout for BDC-4182 in the ", "url": "https://www.investing.com/news/analyst-ratings/rodman--renshaw-initiates-bolt-biotherapeutics-stock-with-buy-rating-93CH-4715582", "source_name": "Investing.com", "published_at": "2026-05-28T21:10:16", "published_display": "28 May 2026 21:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bolt Biotherapeutics, Inc. (BOLT) reports Q1 loss, lags revenue estimates", "summary": "Bolt Biotherapeutics, Inc. (BOLT) reported a wider-than-anticipated loss and revenue that fell short of analyst estimates for the first quarter. The company announced a loss of $0.62 per share, exceeding the average analyst estimate of a $0.57 loss, and posted revenues of $2.20 m", "url": "https://www.msn.com/en-us/money/topstocks/bolt-biotherapeutics-inc-bolt-reports-q1-loss-lags-revenue-estimates/ar-AA2326va?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-05-21T03:40:20", "published_display": "21 May 2026 03:40", "sentiment": "negative", "sentiment_pct": 27, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update", "summary": "Bolt Biotherapeutics announced its first quarter 2026 financial results, highlighting that its cash balance of $23.9 million is expected to fund operations into 2027. The company is progressing with its BDC-4182 Phase 1/2 study for gastric and gastroesophageal cancer, with initia", "url": "https://www.manilatimes.net/2026/05/13/tmt-newswire/globenewswire/bolt-biotherapeutics-reports-first-quarter-2026-financial-results-and-provides-business-update/2342262", "source_name": "The Manila Times", "published_at": "2026-05-13T13:09:15", "published_display": "13 May 2026 13:09", "sentiment": "positive", "sentiment_pct": 62, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bolt Biotherapeutics Inc.: Q1 Earnings Snapshot", "summary": "Bolt Biotherapeutics Inc. reported a Q1 loss of $7.2 million, or $4.31 per share, with unspecified revenue for the period. The company's shares closed at $5.96 on Tuesday, remaining below their previous year's trading price of $7.50. This financial snapshot was generated using da", "url": "https://www.standard-journal.com/ap/business/bolt-biotherapeutics-inc-q1-earnings-snapshot/article_09b460c1-f83d-561e-b4ba-3657bd4eb9d3.html", "source_name": "standard-journal.com", "published_at": "2026-05-13T01:09:45", "published_display": "13 May 2026 01:09", "sentiment": "negative", "sentiment_pct": 14, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Bolt Projects Holdings Announces Delisting From Nasdaq and SEC Deregistration", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxNeEtIcXJXS0wwSnlPV21ma0dwWHlyYUFtYjV6VGtZbWs5STFiWjN5TnZNeU5JSE11UnJwWU5mOExqR3ZUZld3UEYxcUpwMmVsSUYyeTIzTkhXVWNHaDB2a2FIbFlIZDNjNDVmRF9wb1FIOU1GQi15aDVEejQ1anBOSDBQRHFXaHA3a25wTzBiUEt3SmY5eVZQeFdGTUE4SW83REdoWGpZM21wNjRfMUJPdmt1UFZPUHVQXzJkRlBMeGc3NXdCd3RWTGJ3czR1NHM?oc=5", "source_name": "Business Wire", "published_at": "2026-02-19T08:00:00+00:00", "published_display": "19 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bolt Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - BOLT", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygJBVV95cUxNTTJWWFAzN1NqWHA3ZDNETERncXN6SHEzdzAzeHJUYTVDdmJzZHRjM0ZqaUlNMllLVVV6ODNxX0tvLTNqTlYxZlMybGxwNGYwamtVeEdNSlE0VENIUjFQOERRc290bVlQckhtSWphazRfbWJYQzNfdHdhYXpiWUp4cWgybXlPX25XRXJUbmZQbmQ4cjdWakFITUlQelI2ZFlydkNYbXVaYjVsOEE0elRvcE1kRlFoeG1wRVZUVUJtbVVsNmJ5TEVzMUcwU2hHXzlhMkliRjg4eGowMTl3NDlnZXpGOUpCUndGLXRRMDFUWkE3U2tITWdzMlNlWmRDNjRRZTJ5a3JQM2dHSHdvd3VNcEdLQUFYcDNhMWNzbE43VXVmb002NERUc1RCUjRfTHBqVlUzRlFpaElfY05FX2lWOW8ySzZ3R2Z0YkE?oc=5", "source_name": "PR Newswire", "published_at": "2024-09-03T07:00:00+00:00", "published_display": "03 Sep 2024 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bolt Biotherapeutics (BOLT) Stock Forecast and Price Target 2026 $BOLT", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTFBGS0RzaXFOdWs0eTk3N3NYV1ZoTlBJUlY4d1Y4a1g3Vm5IOVhNTU9qZ0VTeFR6cmdSQ2lJcFZCRmpjUElMMXN1V3R4ZlpJV3ZOMHlKS0s0UTNTcy1yU25BRVppdTNwdw?oc=5", "source_name": "MarketBeat", "published_at": "2024-05-11T13:36:49+00:00", "published_display": "11 May 2024 13:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I buy Bolt Biotherapeutics (BOLT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE5TZmxHa3VnUlRVVmhCN25YZDRDVklIcEVwYmFSN0Q2VHZwYUdxcFpvWGhDc3Y1WG9DSE5WTm5IbURsN0RqNGhnV1BVN25FYXFEVTdMMGl5dWxQTm4zckZLV2YwczE2aFBsT0NDZw?oc=5", "source_name": "Zacks Investment Research", "published_at": "2016-08-23T10:03:43+00:00", "published_display": "23 Aug 2016 10:03", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bolt Biotherapeutics (BOLT) Stock Price, News & Analysis $BOLT", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE1GZFk3c0RDVmJVYUxTRzI3U3UyU0ZLQkZBZHpoV3VhVFVQRVBlR29YM3JWUFlfZTM0LWhZSUpTRmwtVlZjTEJyZDg2UUlib3kyeTVlVTVlY3ByZw?oc=5", "source_name": "MarketBeat", "published_at": "2016-08-16T09:32:12+00:00", "published_display": "16 Aug 2016 09:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "BOLT Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "Bolt Biotherapeutics, Inc. (BOLT) has a current stock price of $4.28, having increased by 1.79% in the past 24 hours. Analysts provide a wide forecast range for BOLT, with a maximum estimate of $75.00 and a minimum of $7.00. The company's stock has experienced a significant decre", "url": "https://www.tradingview.com/symbols/NASDAQ-BOLT/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T20:10:57", "published_display": "26 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bolt Biotherapeutics Inc (BOLT) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Bolt Biotherapeutics Inc (BOLT) has a weak financial status with a current financial score of 5.62, ranking low within the Biotechnology & Medical Research industry. The company's operating efficiency is low, demonstrated by a significant year-over-year revenue decrease of 97.87%", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bolt/financial-health", "source_name": "TradingKey", "published_at": "2026-06-26T20:10:57", "published_display": "26 Jun 2026 20:10", "sentiment": "negative", "sentiment_pct": 19, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A419U9 Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Bolt Biotherapeutics, Inc. (A419U9) stock, including analyst price targets and ratings. It also details the company's financial performance, such as recent earnings and revenue, upcoming earnings dates, and employee count. The article notes th", "url": "https://www.tradingview.com/symbols/LSX-A419U9/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T14:40:12", "published_display": "26 Jun 2026 14:40", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bolt Biotherapeutics, Inc. Actuals & Estimates (MUN:6LP0)", "summary": "This article provides financial actuals and estimates for Bolt Biotherapeutics, Inc. (MUN:6LP0), including analyst forecasts for its stock price, upcoming earnings reports, and past financial performance. It highlights key metrics like earnings per share, revenue, net income, EBI", "url": "https://www.tradingview.com/symbols/MUN-6LP0/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T21:41:15", "published_display": "25 Jun 2026 21:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Bolt Biotherapeutics, Inc. \u2013 NASDAQ:BOLT", "summary": "This article provides financial information for Bolt Biotherapeutics, Inc. (NASDAQ: BOLT), specifically focusing on its enterprise value to revenue forward. The content appears to be a stub or a placeholder page from TradingView, indicating where more detailed financial metrics f", "url": "https://www.tradingview.com/symbols/NASDAQ-BOLT/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T19:40:12", "published_display": "25 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Bolt Biotherapeutics, Inc. \u2013 NASDAQ:BOLT", "summary": "The article discusses the \"Price to book forward\" metric for Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) as presented on TradingView. It specifies that this financial data point is for the BOLT Nasdaq Stock Market, with the market currently closed and no trades. The article is prim", "url": "https://www.tradingview.com/symbols/NASDAQ-BOLT/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T19:12:17", "published_display": "25 Jun 2026 19:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "6LP0 Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Bolt Biotherapeutics, Inc. (6LP0) stock. It includes analyst opinions on future prices, past earnings, revenue, net income, and confirms that the company does not pay dividends. The report also details the company's employee c", "url": "https://www.tradingview.com/symbols/MUN-6LP0/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T02:42:51", "published_display": "25 Jun 2026 02:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bolt Biotherapeutics Inc (BOLT) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Bolt Biotherapeutics Inc (BOLT), detailing analyst ratings, price targets, and revenue expectations. The company currently holds an earnings forecast score of 7.00 within the Biotechnology & Medical Research industry, with an average", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bolt/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T17:39:26", "published_display": "18 Jun 2026 17:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bolt Biotherapeutics Inc (BOLT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey examines Bolt Biotherapeutics Inc. (BOLT)'s revenue breakdown. It states that relevant data regarding business segments, regional revenue, and profit contribution has not yet been disclosed by the company. The stock closed at $4.030, down 4.28%.", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bolt/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T17:17:42", "published_display": "18 Jun 2026 17:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bolt Biotherapeutics Inc (BOLT) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article provides an overview of Bolt Biotherapeutics Inc (BOLT)'s shareholder structure, detailing its major shareholders and institutional holdings. It lists key shareholders like Sofinnova Investments, Inc. and Vivo Capital, LLC, categorizes shareholders by type, and prese", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bolt/ownership", "source_name": "TradingKey", "published_at": "2026-06-18T17:17:42", "published_display": "18 Jun 2026 17:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bolt Biotherapeutics Inc (BOLT) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Bolt Biotherapeutics Inc (BOLT), detailing its current price momentum score, support and resistance levels, and technical indicator readings. It shows that BOLT has a price momentum score of 6.62 and is trading between a resistance of", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bolt/technical", "source_name": "TradingKey", "published_at": "2026-06-18T16:39:39", "published_display": "18 Jun 2026 16:39", "sentiment": "negative", "sentiment_pct": 12, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bolt Biotherapeutics Inc (BOLT) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Bolt Biotherapeutics Inc's (BOLT) dividend history and stock split events. It indicates that the company has not distributed any dividends in the past five years. However, it lists a significant stock split event described as a 20-for-1 merger", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bolt/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T16:17:42", "published_display": "18 Jun 2026 16:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bolt Biotherapeutics Inc (BOLT) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "This article provides a risk assessment for Bolt Biotherapeutics Inc (BOLT), categorizing it within the Biotechnology & Medical Research industry. It details the company's current risk assessment score, beta value, and various volatility and liquidity metrics. The analysis indica", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bolt/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-18T09:12:07", "published_display": "18 Jun 2026 09:12", "sentiment": "negative", "sentiment_pct": 40, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bolt Biotherapeutics Inc (BOLT) Institutional Confidence", "summary": "Bolt Biotherapeutics Inc (BOLT) has an institutional shareholding score of 3.00, placing it 193rd out of 388 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 26.88%, which is a quarter-over-quarter decrease of 51.40%. James Sim", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bolt/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T05:12:07", "published_display": "18 Jun 2026 05:12", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bolt Biotherapeutics Inc (BOLT) Valuation: PE, PB & Fair Value Analysis", "summary": "Bolt Biotherapeutics Inc (BOLT) has a current valuation score of 9.01, placing it 67th out of 388 companies in the Biotechnology & Medical Research industry. The company's P/E ratio stands at -0.26, reflecting a significant drop from its recent high but an increase from its recen", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bolt/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T00:12:07", "published_display": "18 Jun 2026 00:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bolt Biotherapeutics (BOLT) director receives 5,000 stock options at $4.43 strike", "summary": "Bolt Biotherapeutics director Nicole Onetto was granted 5,000 stock options with an exercise price of $4.43 per share. These options are a compensation-related grant, not an open-market purchase, and will vest on the earlier of June 9, 2027, or the day before the next annual stoc", "url": "https://www.stocktitan.net/sec-filings/BOLT/form-4-bolt-biotherapeutics-inc-insider-trading-activity-569d1bf5212a.html", "source_name": "Stock Titan", "published_at": "2026-06-12T01:40:33", "published_display": "12 Jun 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bolt Biotherapeutics (BOLT) director receives 5,000 stock options at $4.43 exercise price", "summary": "Bolt Biotherapeutics director Laura Berner was granted 5,000 stock options with an exercise price of $4.43 per share, expiring on June 9, 2036. The options will vest on the earlier of June 9, 2027, or the day before the next annual stockholders' meeting, subject to continuous ser", "url": "https://www.stocktitan.net/sec-filings/BOLT/form-4-bolt-biotherapeutics-inc-insider-trading-activity-cddb88819838.html", "source_name": "Stock Titan", "published_at": "2026-06-11T20:39:07", "published_display": "11 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bolt Biotherapeutics (NASDAQ: BOLT) director receives 5,000-share stock option grant", "summary": "Bolt Biotherapeutics director Jakob Dupont was granted a stock option for 5,000 shares of common stock with an exercise price of $4.43 per share, expiring on June 9, 2036. The options will vest on the earlier of June 9, 2027, or the day before the next annual stockholder meeting,", "url": "https://www.stocktitan.net/sec-filings/BOLT/form-4-bolt-biotherapeutics-inc-insider-trading-activity-5b6e204fdc90.html", "source_name": "Stock Titan", "published_at": "2026-06-11T20:39:07", "published_display": "11 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bolt Biotherapeutics (BOLT) director receives 5,000 stock options at $4.43 strike price", "summary": "Bolt Biotherapeutics director Brian O\u2019Callaghan was granted 5,000 stock options with an exercise price of $4.43 per share, expiring on June 9, 2036. The options will vest on the earlier of June 9, 2027, or the day before the next annual stockholder meeting, provided continuous se", "url": "https://www.stocktitan.net/sec-filings/BOLT/form-4-bolt-biotherapeutics-inc-insider-trading-activity-b684a1f75138.html", "source_name": "Stock Titan", "published_at": "2026-06-11T20:39:07", "published_display": "11 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bolt Biotherapeutics (NASDAQ: BOLT) grants director options for 5,000 shares", "summary": "Bolt Biotherapeutics (NASDAQ: BOLT) director Kathleen LaPorte was granted stock options for 5,000 shares with an exercise price of $4.43 per share, expiring on June 9, 2036. The options will vest on the earlier of June 9, 2027, or the day before the next annual stockholder meetin", "url": "https://www.stocktitan.net/sec-filings/BOLT/form-4-bolt-biotherapeutics-inc-insider-trading-activity-db5570814a17.html", "source_name": "Stock Titan", "published_at": "2026-06-11T20:39:07", "published_display": "11 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BOLT - Bolt Biotherapeutics Inc Stock Price and Quote", "summary": "This article provides detailed financial data and news for Bolt Biotherapeutics Inc. (BOLT), including its stock price, key financial metrics, insider transactions, and a chronological list of company news and analyst ratings. The company is a clinical-stage biopharmaceutical fir", "url": "https://finviz.com/stock?t=BOLT", "source_name": "Finviz", "published_at": "2026-06-02T10:10:19", "published_display": "02 Jun 2026 10:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bolt Biotherapeutics Price Target Announced at $22.00/Share by Rodman & Renshaw", "summary": "Rodman & Renshaw has initiated coverage on Bolt Biotherapeutics (NASDAQ:BOLT), assigning a \"Buy\" rating and setting a price target of $22.00 per share. This target suggests a potential upside of 1150% from the stock's previous closing price.", "url": "https://www.moomoo.com/news/post/70782663/bolt-biotherapeutics-price-target-announced-at-22-00-share-by", "source_name": "Moomoo", "published_at": "2026-05-29T19:39:54", "published_display": "29 May 2026 19:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rodman & Renshaw initiates Bolt Biotherapeutics stock with buy rating By Investing.com", "summary": "Rodman & Renshaw initiated coverage on Bolt Biotherapeutics (NASDAQ:BOLT) with a buy rating and a $22.00 price target. The firm cited the company's Claudin 18.2 immune-stimulating antibody conjugate platform and a near-term clinical readout for BDC-4182 expected in Q3 2026 as key", "url": "https://in.investing.com/news/stock-market-news/rodman--renshaw-initiates-bolt-biotherapeutics-stock-with-buy-rating-93CH-5430912", "source_name": "Investing.com India", "published_at": "2026-05-29T08:39:07", "published_display": "29 May 2026 08:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rodman & Renshaw initiates Bolt Biotherapeutics stock with buy rating", "summary": "Rodman & Renshaw has initiated coverage on Bolt Biotherapeutics (NASDAQ:BOLT) with a \"buy\" rating and a price target of $22.00, citing the company's Claudin 18.2 immune-stimulating antibody conjugate platform. The firm anticipates a near-term clinical readout for BDC-4182 in the ", "url": "https://www.investing.com/news/analyst-ratings/rodman--renshaw-initiates-bolt-biotherapeutics-stock-with-buy-rating-93CH-4715582", "source_name": "Investing.com", "published_at": "2026-05-28T21:10:16", "published_display": "28 May 2026 21:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bolt Biotherapeutics, Inc. (BOLT) reports Q1 loss, lags revenue estimates", "summary": "Bolt Biotherapeutics, Inc. (BOLT) reported a wider-than-anticipated loss and revenue that fell short of analyst estimates for the first quarter. The company announced a loss of $0.62 per share, exceeding the average analyst estimate of a $0.57 loss, and posted revenues of $2.20 m", "url": "https://www.msn.com/en-us/money/topstocks/bolt-biotherapeutics-inc-bolt-reports-q1-loss-lags-revenue-estimates/ar-AA2326va?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-05-21T03:40:20", "published_display": "21 May 2026 03:40", "sentiment": "negative", "sentiment_pct": 27, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update", "summary": "Bolt Biotherapeutics announced its first quarter 2026 financial results, highlighting that its cash balance of $23.9 million is expected to fund operations into 2027. The company is progressing with its BDC-4182 Phase 1/2 study for gastric and gastroesophageal cancer, with initia", "url": "https://www.manilatimes.net/2026/05/13/tmt-newswire/globenewswire/bolt-biotherapeutics-reports-first-quarter-2026-financial-results-and-provides-business-update/2342262", "source_name": "The Manila Times", "published_at": "2026-05-13T13:09:15", "published_display": "13 May 2026 13:09", "sentiment": "positive", "sentiment_pct": 62, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bolt Biotherapeutics Inc.: Q1 Earnings Snapshot", "summary": "Bolt Biotherapeutics Inc. reported a Q1 loss of $7.2 million, or $4.31 per share, with unspecified revenue for the period. The company's shares closed at $5.96 on Tuesday, remaining below their previous year's trading price of $7.50. This financial snapshot was generated using da", "url": "https://www.standard-journal.com/ap/business/bolt-biotherapeutics-inc-q1-earnings-snapshot/article_09b460c1-f83d-561e-b4ba-3657bd4eb9d3.html", "source_name": "standard-journal.com", "published_at": "2026-05-13T01:09:45", "published_display": "13 May 2026 01:09", "sentiment": "negative", "sentiment_pct": 14, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bolt Projects Holdings Announces Delisting From Nasdaq and SEC Deregistration", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxNeEtIcXJXS0wwSnlPV21ma0dwWHlyYUFtYjV6VGtZbWs5STFiWjN5TnZNeU5JSE11UnJwWU5mOExqR3ZUZld3UEYxcUpwMmVsSUYyeTIzTkhXVWNHaDB2a2FIbFlIZDNjNDVmRF9wb1FIOU1GQi15aDVEejQ1anBOSDBQRHFXaHA3a25wTzBiUEt3SmY5eVZQeFdGTUE4SW83REdoWGpZM21wNjRfMUJPdmt1UFZPUHVQXzJkRlBMeGc3NXdCd3RWTGJ3czR1NHM?oc=5", "source_name": "Business Wire", "published_at": "2026-02-19T08:00:00+00:00", "published_display": "19 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bolt Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - BOLT", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygJBVV95cUxNTTJWWFAzN1NqWHA3ZDNETERncXN6SHEzdzAzeHJUYTVDdmJzZHRjM0ZqaUlNMllLVVV6ODNxX0tvLTNqTlYxZlMybGxwNGYwamtVeEdNSlE0VENIUjFQOERRc290bVlQckhtSWphazRfbWJYQzNfdHdhYXpiWUp4cWgybXlPX25XRXJUbmZQbmQ4cjdWakFITUlQelI2ZFlydkNYbXVaYjVsOEE0elRvcE1kRlFoeG1wRVZUVUJtbVVsNmJ5TEVzMUcwU2hHXzlhMkliRjg4eGowMTl3NDlnZXpGOUpCUndGLXRRMDFUWkE3U2tITWdzMlNlWmRDNjRRZTJ5a3JQM2dHSHdvd3VNcEdLQUFYcDNhMWNzbE43VXVmb002NERUc1RCUjRfTHBqVlUzRlFpaElfY05FX2lWOW8ySzZ3R2Z0YkE?oc=5", "source_name": "PR Newswire", "published_at": "2024-09-03T07:00:00+00:00", "published_display": "03 Sep 2024 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bolt Biotherapeutics (BOLT) Stock Forecast and Price Target 2026 $BOLT", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTFBGS0RzaXFOdWs0eTk3N3NYV1ZoTlBJUlY4d1Y4a1g3Vm5IOVhNTU9qZ0VTeFR6cmdSQ2lJcFZCRmpjUElMMXN1V3R4ZlpJV3ZOMHlKS0s0UTNTcy1yU25BRVppdTNwdw?oc=5", "source_name": "MarketBeat", "published_at": "2024-05-11T13:36:49+00:00", "published_display": "11 May 2024 13:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I buy Bolt Biotherapeutics (BOLT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE5TZmxHa3VnUlRVVmhCN25YZDRDVklIcEVwYmFSN0Q2VHZwYUdxcFpvWGhDc3Y1WG9DSE5WTm5IbURsN0RqNGhnV1BVN25FYXFEVTdMMGl5dWxQTm4zckZLV2YwczE2aFBsT0NDZw?oc=5", "source_name": "Zacks Investment Research", "published_at": "2016-08-23T10:03:43+00:00", "published_display": "23 Aug 2016 10:03", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bolt Biotherapeutics (BOLT) Stock Price, News & Analysis $BOLT", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE1GZFk3c0RDVmJVYUxTRzI3U3UyU0ZLQkZBZHpoV3VhVFVQRVBlR29YM3JWUFlfZTM0LWhZSUpTRmwtVlZjTEJyZDg2UUlib3kyeTVlVTVlY3ByZw?oc=5", "source_name": "MarketBeat", "published_at": "2016-08-16T09:32:12+00:00", "published_display": "16 Aug 2016 09:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 95, "total_relevant": 40, "sentiment_summary": {"positive": 7, "negative": 10, "neutral": 23, "score": 48, "total": 40, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "earnings", "primary_label": "Earnings", "confidence": 74, "events": [{"event": "earnings", "label": "Earnings", "weight": 8.8, "count": 18}, {"event": "general", "label": "Market update", "weight": 7.5, "count": 13}, {"event": "analyst", "label": "Analyst action", "weight": 2.2, "count": 4}, {"event": "guidance", "label": "Guidance", "weight": 1.1, "count": 2}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 7, "negative_events": 10}, "market_context": {"has_market_context": true, "latest_close": 4.42, "latest_week": "2026-07-17", "one_week_move": 16.9, "four_week_move": 10.8, "twelve_week_move": -8.5, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.49258, "market_dynamics_buy_signal": false, "relative_strength": -22.308864, "fair_value_gap": -63.1, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 40.0493, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+16.9% over one week, +10.8% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 58, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Earnings", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingKey", "count": 9}, {"label": "Market source", "count": 6}, {"label": "TradingView", "count": 6}, {"label": "Stock Titan", "count": 5}, {"label": "simplywall.st", "count": 2}, {"label": "MarketBeat", "count": 2}, {"label": "Finviz", "count": 1}, {"label": "Moomoo", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 32}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 18}, {"label": "Market update", "count": 13}, {"label": "Analyst action", "count": 4}, {"label": "Guidance", "count": 2}, {"label": "Deals and strategy", "count": 1}, {"label": "Balance sheet", "count": 1}, {"label": "Regulatory and legal", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "48/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Earnings", "tone": "neutral", "text": "74/100 classification confidence."}, {"label": "Company focus", "value": "32", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+16.9% over one week, +10.8% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "BOLT Forecast \u2014 Price Target \u2014 Prediction for 2027"}], "updated_at": "2026-07-18T15:15:49.046879+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}